NCT04938921

Brief Summary

The purpose of this study is to assess the percentage of pulmonary venous stenosis after TAPVC repair with sutureless closure.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started May 2019

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 30, 2019

Completed
2 years until next milestone

First Submitted

Initial submission to the registry

June 16, 2021

Completed
9 days until next milestone

First Posted

Study publicly available on registry

June 25, 2021

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2022

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2024

Completed
Last Updated

June 25, 2021

Status Verified

June 1, 2021

Enrollment Period

3 years

First QC Date

June 16, 2021

Last Update Submit

June 23, 2021

Conditions

Keywords

TAPVCSuturelessPulmonary venous stenosis

Outcome Measures

Primary Outcomes (3)

  • The percentage of pulmonary venous stenosis after reparing TAPVC with sutureless technique

    The investigators calculate pulmonary venous score (PVS) based on the mean gradient through each pulmonary vein. Then we sum all the score of each pulmonary vein, range from 0 to 12, and classify to 4 levels. Score 0 if the mean gradient is less than 2mmHg, 1 if it is from 2 to 6,9mmHg, 2 if it is from 7 mmHg and above, and 3 if the vein is occluded. The degree of obstruction is classified as follow: none (0 to 1), mild (2 to 3), moderate (4 to 7), and severe (from 8 and above).

    The investigators assess the PVS at the time of 12 month after the operation.

  • Early mortality (<30 days)

    Early mortality is defined when patients die within 30 days since the operation

    30 days

  • The percentage of pulmonary venous stenosis after reparing TAPVC with sutureless technique

    The investigator calculate pulmonary venous score (PVS) based on the mean gradient through each pulmonary vein. Then we sum all the score of each pulmonary vein, range from 0 to 12, and classify to 4 levels. Score 0 if the mean gradient is less than 2mmHg, 1 if it is from 2 to 6,9mmHg, 2 if it is from 7 mmHg and above, and 3 if the vein is occluded. The degree of obstruction is classified as follow: none (0 to 1), mild (2 to 3), moderate (4 to 7), and severe (from 8 and above).

    The investigators assess the PVS at the time of 18 month after the operation.

Secondary Outcomes (2)

  • Late mortality (> 30 days)

    The investigators assess mortality at the time of 18 month after the operation

  • The percentage of pulmonary venous stenosis after reparing TAPVC with sutureless technique

    The investigators assess the PVS at the time of 6 month after the operation.

Eligibility Criteria

AgeUp to 15 Years
Sexall
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

All patients with TAPVC operated with sutureless closure and be agreed to joint this study by parents from 01/2019 to 06/2024

You may qualify if:

  • All patients with TAPVC operated with sutureless closure and be agreed to join this study by parents from 01/2019 to 06/2024.

You may not qualify if:

  • TAPVC operated with sutureless closure have single ventricle, isomerism or heterotaxy, congenital pulmonary venous stenosis.
  • TAPVC enrolled to study but cannot the obtain the echocardiography at the time of 1 month, 6 month, 12 month and 18 month.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Children's Hospital 1

Ho Chi Minh City, 70000, Vietnam

RECRUITING

MeSH Terms

Conditions

Scimitar Syndrome

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesRespiratory System AbnormalitiesVascular MalformationsCardiovascular AbnormalitiesCardiovascular DiseasesVascular DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

  • Thoi K Ngo, MSC

    Children's Hospital 1

    STUDY DIRECTOR
  • Phuc M Vu, PhD

    University of Medicine and Pharmacy in HCMC

    STUDY DIRECTOR
  • Tuan D Nguyen, MSC

    Children's Hospital 1

    STUDY DIRECTOR
  • Linh NU Truong, PhD

    University of Medicine and Pharmacy in HCMC

    STUDY DIRECTOR

Central Study Contacts

Thanh QL Dinh, MSC

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Target Duration
18 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principle investigator

Study Record Dates

First Submitted

June 16, 2021

First Posted

June 25, 2021

Study Start

May 30, 2019

Primary Completion

June 1, 2022

Study Completion

June 1, 2024

Last Updated

June 25, 2021

Record last verified: 2021-06

Locations